Commentary

Article

State of Science Summit: Chaired by Kathryn Mileham, MD, FACP | Atrium Health Levine Cancer Institute

In Partnership With:

State of Science Summit: Chaired by Kathryn Mileham, MD, FACP | Atrium Health Levine Cancer Institute

State of Science Summit: Chaired by Kathryn Mileham, MD, FACP | Atrium Health Levine Cancer Institute

Speakers

  • Daniel Carrizosa, MD, MS l Atrium Health Levine Cancer Institute
  • Christopher Pallas, MD | Atrium Health Levine Cancer Institute
  • Daniel Haggstrom, MD | Atrium Health Levine Cancer Institute
  • John Heinzerling, MD | Atrium Health Levine Cancer Institute
  • Jeffrey A. Hagen, MD l Atrium Health Levine Cancer Institute

Topics

  • EGFRm NSCLC: Adjuvant to Metastatic
  • Treating Exon 20 Mutations in NSCLC
  • KRAS-Targeted Therapies in NSCLC
  • Current and Emerging Standards in SCLC
  • Updates in Radiation Utilization in all stages of NSCLC and SCLC
  • Early-Stage NSCLC: Perspectives from Surgeon

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Benjamin Levy, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Michael R. Grunwald, MD, FACP
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Related Content
FDA
June 17th 2024

FDA Places Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael Grunwald, MD, of Atrium Health
June 14th 2024

Observational Study Finds Progression Common in Lower-Risk Myelofibrosis

Jubilee Brown, MD, professor, director, Gynecologic Oncology, Atrium Health Levine Cancer Institute
May 13th 2024

Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer

Luis G. Paz-Ares, MD, PhD, chair, Medical Oncology Department, Hospital Universitario 12 de Octubre; associate professor, Universidad Complutense de Madrid
June 11th 2024

Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC

Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC